Deloitte November 7, 2019
It’s been four years since the Deloitte Center for Health Solutions collaborated with the Network for Excellence in Health Innovation (NEHI) to discuss the implications of value-based care on pharmaceutical innovation. Back then, the idea of value-based contracting (VBC) for drugs hadn’t moved much beyond exploring the concept. While there were a few examples here and there, most organizations were still working through the premise. What a difference four years makes. While I wouldn’t say VBCs have become common, the pharmaceutical industry has clearly moved from the talking phase to the doing phase. However, several hurdles still need to be addressed before VBCs can move into the mainstream.
In September, Deloitte assembled a group of thought leaders from across the...
Today's Sponsors
Today's Sponsor